The upcoming quarter’s "xbi stock price forecast" is underpinned by expectations of positive trial readouts, which historically trigger upward moves in biotech ETFs. However, as I have dug further into the story, I am becoming more bullish, and, in my view, those who missed out on the move so far should not fret as 2025 will likely be a breakout year for the company. Below are the top three ways the Trump victory will be bullish for Tesla in 2025: These are some of the stocks moving after the bell: The latest "xbi stock price forecast" points to cautious optimism, with analysts projecting a potential target of $92–$96 over the next quarter, driven by robust biotech sector earnings and steady inflows from institutional investors.